ESK
Asset Logo

Etherstack PLC

πŸ‡¦πŸ‡Ί ASX

πŸ€– TECHNOLOGY

Compare
Add to watchlist
πŸ‘‘ Overview

πŸ“ˆ Performance

πŸ’΅ Cost

πŸ€“ Advanced

πŸ‘¨β€πŸ‘©β€πŸ‘§β€πŸ‘¦ Community

πŸ“ˆ

-4.31%
Annual Growth

5 years average annual growth

πŸ’΅

$ 500
Minimum Order

Due to regulatory requirements

🌏

1
Pearlers Invested

Since January 2020

πŸ‘‘ Overview

Key information
πŸ”Ž Fund Overview

Etherstack Plc engages in the design, development, and deployment of wireless communications software and products. The company is headquartered in Reading, Berkshire. The company went IPO on 2012-09-07. The firm develops software for use in transceivers which enable the transceiver to communicate with a radio network and other transceivers. The company develops network soft switching software that allows network services to be deployed in data centers such as those used by telecommunications carriers. The company also licenses its software and designs to companies who manufacture telecommunication equipment primarily for government public safety agencies and utilities. Its technology and systems include cryptography and key management, defense waveforms, LMR - LTE Interworking, LMR Protocol Stacks, LMR Voice and Data Systems and Tactical and Satellite Systems. The company provides a range of cryptographic solutions that includes FIPS 140-2 Cryptographic Module and P25 Security Dongle.

πŸ“ˆ Performance

Price History

+19.58%

1M

1Y

10Y

Graph

Table

Unsure how much or often to invest?
πŸ—“οΈ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out β†’
πŸ’΅ Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out β†’
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out β†’

πŸ’΅ Costs

πŸ’΅

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

πŸ’Ό

N/A
Management Fee

Included in unit price, not charged by Pearler

πŸ’Έ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πŸ’Έ Net fee calculator

πŸ€“ Advanced information

Technical Info

πŸ’° Price*

$0.20

*Price may be up to 24 hours old

πŸ‘©β€πŸ‘©β€πŸ‘¦ Community Insights

How our community is investing

🌏 Pearlers invested in ESK

1

πŸ“Š Total Capital Earnings

$5K

πŸ”ƒ Average investment frequency

8 weeks

πŸ’΅ Average investment amount

$2,285

⏰ Last time a customer invested in ESK

127 days
ESK investor breakdown
πŸ’΅ Income of investors

More than 200k

150k - 200k

100k - 150k

100%

50k - 100k

Less than 50k

πŸ‘Ά Age of investors

18 - 25

26 - 34

100%

35 - 90

πŸ™‹ Legal gender of investors

Female

Male

100%

Pearlers who invest in ESK also invest in...

Vanguard Australian Shares Index ETF

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

4.43%

πŸ“Š Share price

$104.33 AUD

🧱 MATERIALS

⛳️ DIVERSIFIED

πŸ’Έ FINANCIALS

Find Out More

Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The firm is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Company’s pharmaceuticals product development includes PRENUMBRA and NEURACTHEL. Its PhotoCosmetics product development includes CYACELLE and DNA Repair Assist and Melanogenesis. PRENUMBRA is a formulation of afamelanotide designed to provide a flexible dose in identified patient groups. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH).

πŸ™Œ Performance (5Yr p.a)

-11.25%

πŸ“Š Share price

$13.04 AUD

🧬 BIOTECHNOLOGY

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

13.28%

πŸ“Š Share price

$134.96 AUD

🌏 GLOBAL

⛳️ DIVERSIFIED

πŸ€– TECHNOLOGY

πŸ“ˆ HIGH PRICE GROWTH

ACDC.AX was created on 2018-08-30 by Global X. The fund's investment portfolio concentrates primarily on theme equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the Solactive Battery ValueChain Index (the Index).

πŸ™Œ Performance (5Yr p.a)

12.72%

πŸ“Š Share price

$82.30 AUD

🌏 GLOBAL

πŸ›οΈ CONSUMER

🏭 INDUSTRIALS

πŸ€– TECHNOLOGY

πŸ“ˆ HIGH PRICE GROWTH

ClearVue Technologies Ltd. engages in the provision of photovoltaic and nano-technology to produce clear glass that generates electricity. The company is headquartered in Perth, Western Australia. The company went IPO on 2018-05-25. The firm operates in the building sustainability solutions sector supplying glazing products responding to the global need for construction decarbonization in a world where buildings and construction contribute nearly 40% of global greenhouse gas emissions. The Company’s solar photovoltaic glazing integrates solar technology into glass and building surfaces helping building owners to reach net zero through the generation of on-site electricity whilst at the same time improving the energy efficiency of the building envelope. The firm provides glazing solutions to various areas, including construction, greenhouses, utilities and infrastructure and demonstrations / research and development. Its products include Clear solar windows, Clear self-powered smart autonomous windows, Clear solar glass greenhouse, Self-powered illuminating facades, and Imaged solar windows.

πŸ™Œ Performance (5Yr p.a)

17.86%

πŸ“Š Share price

$0.27 AUD

πŸ“ˆ HIGH PRICE GROWTH

πŸ”¨ COMMERCIAL SERVICES & SUPPLIES

Want more shares? Try these...

ESPO.AX was created on 2020-09-08 by VanEck. The fund's investment portfolio concentrates primarily on theme equity. The Fund aims to provide investment returns before fees and other costs which track the performance of the Reference Index in Australian dollars. The Fund does not aim to perfectly replicate the Reference Index on a one-to-one basis.

πŸ“Š Share price

$15.60 AUD

πŸ€– TECHNOLOGY

🌳 ENVIRONMENTAL

πŸ“ž COMMUNICATIONS

Estrella Resources Ltd. operates as a mining and exploration company. The company is headquartered in Perth, Western Australia. The company went IPO on 2012-05-09. The Company’s projects include the Carr Boyd Nickel Project and the Spargoville Project. The Carr Boyd Nickel Project covers the Carr Boyd Layered Complex, 75 square kilometers (km2) mafic igneous complex which hosts several nickel and copper sulfide occurrences. The Carr Boyd Layered Complex is in a Tier 1 jurisdiction approximately 80 kilometers (km) north-north-east of Kalgoorlie, Western Australia. Carr Boyd Nickel Project, north of Kalgoorlie in Western Australia, is a focus for the Company-where it has recently made a nickel and copper discovery while drilling into the T5 electromagnetic target. Its two-reverse circulation (RC) drill holes, CBP042 and CBP043, were completed to test the T5 EM conductor plate. The Spargoville Project is located approximately 20 km southwest of Kambalda, Western Australia.

πŸ™Œ Performance (5Yr p.a)

9.09%

πŸ“Š Share price

$0.02 AUD

⛏️ MINING

πŸ“ˆ HIGH PRICE GROWTH

ESGI.AX was created on 2018-03-06 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to provide investment returns before fees and other costs which track the performance of its Reference Index in Australian dollars.

πŸ™Œ Performance (5Yr p.a)

9.79%

πŸ“Š Share price

$36.04 AUD

πŸ“ˆ HIGH PRICE GROWTH

🌏 GLOBAL

πŸ€– TECHNOLOGY

🩺 HEALTH CARE

Compare
Add to watchlist